RMD

ResMed
D

RMD

Arincen97/100B
235.255
USD
-4.06
(-1.69%)
Market Closed
Last updated: · Delayed 15 min
Fair value294.55Plus-20%185Price 235.26478
Q2 FY2027 · Earnings report
EPS estimate 3.03Revenue estimate 1.46B
OverviewFinancialsForecastEarningsDividendsCompany

ResMed executives and insider trading

Michael J. Farrell sold 62,912 shares for 14.60M USD in 12 sales over the last twelve months, the last on 7 October 2026, and bought none on the open market.

Over the last twelve months ResMed's insiders sold 91,974 shares for 21.62M USD in 31 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
31
Shares sold
91,974
Value sold
21.62M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
102.00K USD
0
3 months
2.57M USD
0
6 months
7.45M USD
0
1 year
21.62M USD
0
2 years
61.76M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Michael J. Farrell CEOChief Executive Officer & Chairman5462,91214.60M USD—7 Oct 2026—
Peter C. Farrell Founder, Chair Emeritus & Non-Executive Director8420,9705.01M USD—2 Sept 2026—
Brett A. Sandercock Advisor595,0001.22M USD—1 Apr 2026—
Witte Jan De Director—2,542645.90K USD—25 Nov 2025—
Michael Rider Chief Legal Officer & Secretary68550139.30K USD—23 Oct 2026—

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
23 Oct 2026Michael RiderSale400255.00102.00K USD12,318Form 4
7 Oct 2026Michael J. FarrellSale4,991226.331.13M USD479,803Form 4
8 Sept 2026Michael J. FarrellSale4,991222.441.11M USD466,256Form 4
2 Sept 2026Peter C. FarrellSale970234.73227.69K USD51,803Form 4
7 Aug 2026Michael J. FarrellSale4,991205.691.03M USD466,256Form 4
5 Aug 2026Peter C. FarrellSale8,000225.001.80M USD52,773Form 4
7 Jul 2026Michael J. FarrellSale4,991218.551.09M USD466,223Form 4
8 Jun 2026Michael J. FarrellSale4,991193.96968.06K USD466,256Form 4
7 May 2026Michael J. FarrellSale4,991207.821.04M USD466,223Form 4
7 Apr 2026Michael J. FarrellSale4,991225.501.13M USD466,223Form 4
1 Apr 2026Brett A. SandercockSale1,000224.31224.31K USD83,495Form 4
1 Apr 2026Peter C. FarrellSale2,000225.00450.00K USD60,773Form 4
9 Mar 2026Michael J. FarrellSale4,991251.031.25M USD466,223Form 4
4 Mar 2026Peter C. FarrellSale2,000260.22520.44K USD62,773Form 4
2 Mar 2026Brett A. SandercockSale1,000254.30254.30K USD84,495Form 4

Common questions about ResMed's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.